000 04848nam a22003615i 4500
001 234067
003 ES-VaUE
005 20221220020539.0
007 cr nn 008mamaa
008 130321s2013 xxu| s |||| 0|eng d
020 _a9781627033275
024 7 _a10.1007/978-1-62703-327-5
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
245 1 0 _aGlycosylation Engineering of Biopharmaceuticals
_bMethods and Protocols
_cedited by Alain Beck.
250 _a1st edition 2013
264 1 _aTotowa, NJ
_bHumana Press
_c2013
300 _a1 recurso en línea (XV, 355 páginas)
_b111 ilustraciones, 45 ilustraciones a color
336 _atexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
490 0 _aMethods in Molecular Biology
_x1940-6029
505 0 _aEngineering of Therapeutic and Diagnostic O-Glycans on Recombinant Mucin-Type Immunoglobulin Fusion Proteins Expressed in CHO Cells -- Engineering a Human-Like Glycosylation to Produce Therapeutic Glycoproteins Based on 6-Linked Sialylation in CHO Cells -- Glycoengineered Pichia-Based Expression of Monoclonal Antibodies -- N-Glycosylation Humanization for Production of Therapeutic Recombinant Glycoproteins in Saccharomyces cerevisiae -- Engineering the Baculovirus Genome to Produce Galactosylated Antibodies in Lepidopteran Cells -- Nano LC Chips MS/MS for the Characterization of N-Glycopeptides Generated from Trypsin Digestion of a Monoclonal Antibody -- Cetuximab Fab and Fc N-Glycan Fast Characterization Using IdeS Digestion and Liquid Chromatography Coupled to Electrospray Ionization Mass Spectrometry -- Therapeutic Antibody Glycosylation Analysis: A Contract Research Organization Perspective in the Frame of Batch Release or Comparability Support -- Mass Spectrometric Analysis of O-Linked Oligosaccharides from Various Recombinant Expression Systems -- Assessing Fc Glycan Heterogeneity of Therapeutic Recombinant Monoclonal Antibodies Using NP-HPLC -- Application of Capillary Electrophoresis in Glycoprotein Analysis -- Characterization of Glycoprotein Biopharmaceutical Products by Caliper LC90 CE-SDS Gel Technology -- Hydrophobic Interaction Chromatography to Analyze Glycoproteins -- Lectin Glycoprofiling of Recombinant Therapeutic Interleukin-7 -- Analysis of Monoclonal Antibodies by Sedimentation Velocity Analytical Ultracentrifugation -- Noncovalent Mass Spectrometry for the Characterization of Antibody/Antigen Complexes -- Conformational Analysis of Recombinant Monoclonal Antibodies with Hydrogen/Deuterium Exchange Mass Spectrometry -- Epitope Mapping of Antibodies by Mass Spectroscopy: A Case Study -- Evaluation of Antibody-Dependent Cell Cytotoxicity Using Lactate Deshydrogenase (LDH) Measurement -- Evaluation of Complement Dependent Cytotoxicity Using ATP Measurement and C1q / C4b Binding -- Capture of the Human IgG1 Antibodies by Protein A for the Kinetic Study of h-IgG / FcgR Interaction Using SPR-Based Biosensor Technology -- Mass Spectrometry Protocol for the Absolute Quantification of a Monoclonal Antibody in Serum with Immunopurification.
520 _aGlyco-engineering is being developed as a method to control the composition of carbohydrates and to enhance the pharmacological properties of monoclonal antibodies (mAbs) and other proteins.  In Glycosylation Engineering of Biopharmaceuticals: Methods and Protocols, experts in the field provide readers with production and characterization protocols of glycoproteins and glyco-engineered biopharmaceuticals with a focus on mAbs. The volume is divided in four complementary parts dealing with glyco-engineering of therapeutic proteins, glycoanalytics, glycoprotein complexes characterization, and PK/PD assays for therapeutic antibodies.  Written in the highly successful Methods in Molecular Biology™ series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.   Authoritative and cutting-edge, Glycosylation Engineering of Biopharmaceuticals: Methods and Protocols serves as an ideal guide for scientists striving to push forward the exciting field of engineered biopharmaceuticals.
700 1 _aBeck, Alain
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
776 0 8 _iPrinted edition:
_z9781627033282
776 0 8 _iPrinted edition:
_z9781627033268
776 0 8 _iPrinted edition:
_z9781493962662
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-1-62703-327-5
_z(usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
988 _aSpringer_Protocols_2013
999 _c234067
_d234067